http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20190046489-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ab3413f8184feb74be59b7ed962a5b97 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6845 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1271 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5169 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127 |
| filingDate | 2017-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08b075e8266025d0ee14d0043b6bc436 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3ce346c89bd3145b3206d0d66878f6e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_52baaedada606f9d232081190d102978 |
| publicationDate | 2019-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20190046489-A |
| titleOfInvention | Neuropilin-1 Specific Binding Non-CendR Peptide, Fusion Protein Comprising the Same Fused Thereto and Use Thereof |
| abstract | The present invention relates to an amino acid sequence which is deviated from the -R / KxxR / K motif C-terminal rule (C-end rule / CendR) of the C-terminal amino acid sequence of all ligands and peptides binding to neuropilin 1 (NRP1) , A pharmaceutical composition for the treatment or prevention of cancer, or a neovascularization-related recurrence comprising the fusion protein, the antibody, the small molecule drug, the nanoparticle, the liposome, or the nucleic acid containing the fusion peptide fused with the NRP1 , And diagnostic compositions. In addition, the present invention also provides a polynucleotide encoding a peptide deviating from the C-terminal conformation that binds to NRP1. The present invention also relates to a method for screening peptides deviating from the C-terminal conformation that binds to NRP1. The anticancer antibody fused with a peptide specifically binding to NRP1, deviating from the C-terminal rule according to the present invention, has a property of binding to NRP1, and is selectively accumulated in the tumor tissue when administered in vivo, Of the cells, thereby enhancing the extravasation and increasing the penetration into the tumor tissue. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022168861-A1 |
| priorityDate | 2017-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 339.